Study S001720

Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05726227
Acronym: STEP Young
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 212
Start: 2023-07-07
Primary completion: 2025-10-15
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1266-3808; EUDRACT_NUMBER:2022-502922-41

Registered primary outcomes

Group Kids: Change in body mass index (BMI) [From baseline (week 0) to week 68]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.